Physician profile
Luan Elezi
NPI 1659635092
$2,593.99
in general payments reported to CMS, 2019-2025
25 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $109 · 2021: $632 · 2022: $198 · 2023: $189 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487.07 | 2019-2025 | Wegovy |
| Pfizer INC. | $407.28 | 2019-2023 | |
| Lilly USA, LLC | $328.91 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $238.28 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.67 | 2019-2023 | Jardiance |
| Sunovion Pharmaceuticals INC. | $180.95 | 2019-2021 | |
| Optinose US, INC. | $127.65 | 2019 | |
| Abbvie INC. | $83.85 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.84 | 2022 | |
| Allergan, INC. | $60.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $47.03 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $43.74 | 2019-2020 | |
| Amarin Pharma, INC. | $33.49 | 2021 | |
| Alnylam Pharmaceuticals INC. | $25.39 | 2023 | Amvuttra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $19.50 | 2021 | |
| Adlon Therapeutics L.P. | $19.10 | 2021 | |
| Eisai INC. | $18.72 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $18.64 | 2022 | |
| Mylan Specialty L.P. | $15.78 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.27 | 2023 | Rexulti |
| Jazz Pharmaceuticals INC. | $14.25 | 2020 | |
| Shire North American Group INC | $11.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.61 | 2020 | |
| Merck Sharp & Dohme LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luan Elezi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.